51. Anderson's testimony does not identify the
particular member or members of the "COX-2 chemistry team" who
requested the testing.
52. Anderson testified that he tested the compound
in an in vivo standard G.D. Searle arthritis assay (Exh. 2048
at ¶5).
53. Anderson testified that, based on the results of
the assay, he recognized that SC-60668 had pharmacologically
useful anti-inflammatory activity (Exh. 2048 at ¶6).
54. According to Anderson, he obtained the results
of the arthritis assay on 9 May 1994 and recorded the results
in his notebook (Exh. 2048 at ¶6).
Laura Holtzman
55. Koboldt, Veenhuizen, and Anderson each testified
that the results obtained from testing were reported to Laura
Holtzman for entering into the corporate data base.
56. Laura Holtzman has not testified in the
interference. We have not been pointed to evidence of record
that establishes that Laura Holtzman entered the test results
into the corporate database.
57. We have not been pointed to evidence of record
that establishes that Dr. Huang or Dr. Reitz were aware or
were informed of the results of any of the testing performed
19
Page: Previous 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next
Last modified: November 3, 2007